

FOP Drugs in Research or Development

There has been a surge in FOP research. With your support, the IFOPA is contributing to the advancement of the majority of the drugs currently in the pipeline.

This helpful chart gives you an at-a-glance perspective of where certain drugs are in the process—and shows you which potential treatments the IFOPA has supported with funding.


This is the kind of progress you help make possible through your support of the IFOPA.

Your contributions to the IFOPA fund groundbreaking research, as well as:

- » Support FOP patients and families with new services and programs from the IFOPA
- » Connect more FOP families with each other, and connect them to more resources and information about FOP
- » Create more opportunities for new research and partnerships that advance our understanding about FOP, as well as support the development of new drug candidates

While not every drug will make it to the end and become a prescribed medication, we hope the recent advances in FOP drug development inspire you. Your support helps keep the momentum going.

FOP DRUG DEVELOPMENT (Investigational Treatments)



IND = Investigational New Drug Application

MAA/NDA/BLA = Marketing Authorization Application (EU) / New Drug Application (US) / Biologics License Application (US)

Discovery = Research done before Preclinical that assesses, among other objectives, the identification of new drug candidates, optimization of compounds, and/or mechanism of action

Preclinical = In vivo studies conducted under good laboratory practices to assess toxicity and dosing for human trials

Phase 1 = Studies in humans that assess safety and tolerability of a treatment in a small group of healthy volunteers or patients with the disease of interest

Phase 2 = Studies that further test safety and begin to test efficacy of the drug, often at multiple doses

Phase 3 = Studies that assess safety and efficacy in a larger group of patients and typically compare the drug to a standard of care